-+ 0.00%
-+ 0.00%
-+ 0.00%

Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncology

PUBT·08/18/2026 20:15:18
Listen to the news
Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncology
  • Eikon Therapeutics will join a Cantor Fitzgerald-hosted KOL event on Aug. 20, 2026 at 9:00 a.m. ET.
  • Chairman and CEO Roger M. Perlmutter is scheduled to participate alongside MD Anderson oncologist Timothy A. Yap.
  • Discussion will cover the PARP inhibitor landscape in oncology, including outcomes and limitations of currently available agents.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608181615PRIMZONEFULLFEED9812316) on August 18, 2026, and is solely responsible for the information contained therein.